vs
Journey Medical Corp（DERM）与Rent the Runway, Inc.（RENT）财务数据对比。点击上方公司名可切换其他公司
Journey Medical Corp的季度营收约是Rent the Runway, Inc.的1.5倍（$16.1M vs $10.6M），Rent the Runway, Inc.净利率更高（721.7% vs -7.8%，领先729.5%），Journey Medical Corp同比增速更快（27.3% vs 10.4%），过去两年Journey Medical Corp的营收复合增速更高（11.0% vs 1.0%）
Journey Medical Corp是一家处于商业化阶段的生物制药企业，专注于皮肤病治疗领域，研发、生产并销售处方及非处方皮肤用药，覆盖痤疮、特应性皮炎、皮肤真菌感染等适应症，主要服务美国市场的医疗机构与患者。
Rent the Runway Inc.是总部位于纽约的美国电商平台，由珍妮弗·海曼与珍妮弗·弗莱斯于2009年11月创立，主打设计师品牌服饰与配饰的租赁、订阅以及购买服务，是设计师服饰共享租赁模式的开创平台之一。
DERM vs RENT — 直观对比
营收规模更大
DERM
是对方的1.5倍
$10.6M
营收增速更快
DERM
高出16.9%
10.4%
净利率更高
RENT
高出729.5%
-7.8%
两年增速更快
DERM
近两年复合增速
1.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $10.6M |
| 净利润 | $-1.2M | $76.5M |
| 毛利率 | — | -126.4% |
| 营业利润率 | -2.8% | -152.8% |
| 净利率 | -7.8% | 721.7% |
| 营收同比 | 27.3% | 10.4% |
| 净利润同比 | -182.0% | 504.8% |
| 每股收益（稀释后） | $-0.04 | $13.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DERMRENT
| Q4 25 | $16.1M | $10.6M | ||
| Q3 25 | $17.0M | $11.7M | ||
| Q2 25 | $15.0M | $7.6M | ||
| Q1 25 | $13.1M | $11.8M | ||
| Q4 24 | $12.6M | $9.6M | ||
| Q3 24 | $14.6M | $10.4M | ||
| Q2 24 | $14.9M | $8.9M | ||
| Q1 24 | $13.0M | $10.4M |
净利润DERMRENT
| Q4 25 | $-1.2M | $76.5M | ||
| Q3 25 | $-2.3M | $-26.4M | ||
| Q2 25 | $-3.8M | $-26.1M | ||
| Q1 25 | $-4.1M | $-13.4M | ||
| Q4 24 | $1.5M | $-18.9M | ||
| Q3 24 | $-2.4M | $-15.6M | ||
| Q2 24 | $-3.4M | $-22.0M | ||
| Q1 24 | $-10.4M | $-24.8M |
毛利率DERMRENT
| Q4 25 | — | -126.4% | ||
| Q3 25 | — | -92.3% | ||
| Q2 25 | — | -168.4% | ||
| Q1 25 | — | -71.2% | ||
| Q4 24 | 82.3% | -122.9% | ||
| Q3 24 | 63.9% | -98.1% | ||
| Q2 24 | 56.0% | -131.5% | ||
| Q1 24 | 47.7% | -93.3% |
营业利润率DERMRENT
| Q4 25 | -2.8% | -152.8% | ||
| Q3 25 | -9.0% | -171.8% | ||
| Q2 25 | -19.2% | -259.2% | ||
| Q1 25 | -25.3% | -65.3% | ||
| Q4 24 | 17.7% | -142.7% | ||
| Q3 24 | -19.8% | -92.3% | ||
| Q2 24 | -19.7% | -185.4% | ||
| Q1 24 | -77.4% | -185.6% |
净利率DERMRENT
| Q4 25 | -7.8% | 721.7% | ||
| Q3 25 | -13.6% | -225.6% | ||
| Q2 25 | -25.3% | -343.4% | ||
| Q1 25 | -31.0% | -113.6% | ||
| Q4 24 | 12.1% | -196.9% | ||
| Q3 24 | -16.3% | -150.0% | ||
| Q2 24 | -22.6% | -247.2% | ||
| Q1 24 | -80.1% | -238.5% |
每股收益（稀释后）DERMRENT
| Q4 25 | $-0.04 | $13.65 | ||
| Q3 25 | $-0.09 | $-6.55 | ||
| Q2 25 | $-0.16 | $-6.58 | ||
| Q1 25 | $-0.18 | $-2.72 | ||
| Q4 24 | $0.10 | $-4.70 | ||
| Q3 24 | $-0.12 | $-4.17 | ||
| Q2 24 | $-0.17 | $-6.03 | ||
| Q1 24 | $-0.53 | $-5.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.1M | $50.7M |
| 总债务越低越好 | $25.3M | — |
| 股东权益账面价值 | $31.9M | $-35.1M |
| 总资产 | $94.6M | $231.0M |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资DERMRENT
| Q4 25 | $24.1M | $50.7M | ||
| Q3 25 | $24.9M | $43.6M | ||
| Q2 25 | $20.3M | $70.4M | ||
| Q1 25 | $21.1M | $77.4M | ||
| Q4 24 | $20.3M | $74.1M | ||
| Q3 24 | $22.5M | $76.6M | ||
| Q2 24 | $23.9M | $82.0M | ||
| Q1 24 | $24.1M | $84.0M |
总债务DERMRENT
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | $340.6M | ||
| Q1 25 | $25.0M | $333.7M | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
股东权益DERMRENT
| Q4 25 | $31.9M | $-35.1M | ||
| Q3 25 | $25.9M | $-232.1M | ||
| Q2 25 | $19.2M | $-207.1M | ||
| Q1 25 | $21.5M | $-182.5M | ||
| Q4 24 | $20.1M | $-171.2M | ||
| Q3 24 | $10.9M | $-154.5M | ||
| Q2 24 | $11.3M | $-141.3M | ||
| Q1 24 | $13.0M | $-122.3M |
总资产DERMRENT
| Q4 25 | $94.6M | $231.0M | ||
| Q3 25 | $85.2M | $219.0M | ||
| Q2 25 | $81.2M | $245.3M | ||
| Q1 25 | $85.0M | $240.0M | ||
| Q4 24 | $80.2M | $251.6M | ||
| Q3 24 | $64.0M | $257.4M | ||
| Q2 24 | $65.2M | $278.4M | ||
| Q1 24 | $66.6M | $278.5M |
负债/权益比DERMRENT
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.3M | $-1.4M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | -0.02× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DERMRENT
| Q4 25 | $-6.3M | $-1.4M | ||
| Q3 25 | $-2.4M | $-10.5M | ||
| Q2 25 | $-942.0K | $8.3M | ||
| Q1 25 | $-2.8M | $1.4M | ||
| Q4 24 | $2.2M | $4.7M | ||
| Q3 24 | $-1.2M | $2.2M | ||
| Q2 24 | $-5.2M | $4.6M | ||
| Q1 24 | $-5.0M | $-8.0M |
现金转化率DERMRENT
| Q4 25 | — | -0.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
RENT
暂无分部数据
